North America Antibody Drug Conjugates Market Analysis and Forecast by Size, Share, Growth, Trends 2031
North America Antibody Drug Conjugates Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology (Cleavable Linker and Non-cleavable Linker), Application (Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others), Target (HER2, CD22, CD30, and Others), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies)
- Status : Published
- Report Code : TIPRE00041550
- Category : Life Sciences
- No. of Pages : 198
- Available Report Formats :
The North America Antibody Drug Conjugates Market size is expected to reach US$ 20,332.5 Million by 2031 from US$ 4,432.3 Million in 2023. The market is estimated to record a CAGR of 21.0% from 2023 to 2031.
Executive Summary and North America Antibody Drug Conjugates Market Analysis:The North American antibody-drug conjugate (ADC) market, covering the US, Canada, and Mexico, is growing substantially, driven mainly by the increasing number of cancer cases in the region. Increased demand for effective and targeted cancer drugs has spurred research and development, resulting in a strong pipeline of next-generation ADC products. The US leads the local market owing to sophisticated healthcare infrastructure, robust drug presence, and frequent approval of products by regulatory agencies like the FDA. Canada and Mexico are also contributing to market growth through rising healthcare investments and better access to cancer therapy. Rising awareness of the advantages of novel conjugates in enhancing treatment accuracy and reducing side effects is also supporting uptake. Additionally, the rise in strategic mergers, alliances, and partnerships of top biotech and pharmaceutical players is driving innovation, broadening clinical uses, and propelling the overall growth of North America's ADC market.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
North America Antibody Drug Conjugates Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- By Technology, the North America Antibody Drug Conjugates Market is segmented into Cleavable Linker and Non-cleavable Linker. Cleavable Linker held the largest share of the market in 2023.
- By Application, the North America Antibody Drug Conjugates Market is segmented into Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others. Breast Cancer held the largest share of the market in 2023.
- By Target, the North America Antibody Drug Conjugates Market is segmented into HER2, CD22, CD30, and Others. HER2 held the largest share of the market in 2023.
- By Distribution Channel, the North America Antibody Drug Conjugates Market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Retail Pharmacies held the largest share of the market in 2023.
Strategic investments such as mergers, acquisitions, partnerships, and collaborations among key players in the antibody-drug conjugates (antibody-drug conjugates) market significantly influence its growth and development. These strategies enable companies to pool resources, share expertise, and leverage complementary strengths to enhance their competitive edge in a rapidly evolving landscape. Amid the search for innovative cancer therapies, antibody-drug conjugates have gained attention for their ability to selectively target and destroy cancer cells while sparing healthy tissues, thereby minimizing side effects. Consequently, major pharmaceutical and biotechnology firms are increasingly engaging in strategic alliances to accelerate the development and commercialization of antibody-drug conjugates.
As the market becomes more competitive, companies seek to acquire or merge with other firms that have promising antibody-drug conjugate technologies or candidates in their pipelines. For instance, larger pharmaceutical companies acquire smaller biotech firms specializing in antibody-drug conjugate development to quickly incorporate advanced technologies into their existing product lines. Such acquisitions help the acquiring company enhance its portfolio and gain access to novel linker technologies, payloads, and targeting mechanisms that can improve the efficacy and safety profiles of its therapeutics. In October 2024, GlycoMimetics, Inc. entered into an acquisition agreement with Crescent Biopharma, Inc., a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, the company plans to operate under the name Crescent Biopharma, Inc. In March 2024, Johnson & Johnson acquired Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform, to design and develop next-generation antibody-drug conjugates. The competitive landscape in the antibody-drug conjugates market is characterized by a high level of activity from key players engaging in strategic investments. This dynamism encourages innovation and improvement as companies strive to differentiate their products and establish leadership in the market. The influx of capital investment into oncology attracts new entrants, leading to a more vibrant ecosystem, encouraging innovative ideas. Strategic investments through mergers, acquisitions, partnerships, and collaborations play a pivotal role in driving the growth of the antibody-drug conjugates market. These investments create a synergistic environment by enhancing product portfolios, improving manufacturing processes, and fostering innovation to propel the development of effective and targeted cancer therapies.
North America Antibody Drug Conjugates Market Country InsightsBy country, the North America Antibody Drug Conjugates Market is segmented into the United States, Canada, and Mexico. The United States held the largest share in 2023.
The highest number of antibody-drug conjugates has been approved in the US. Several antibody-drug conjugates are in the pipeline in the US. Antibody-drug conjugates have been developed with advanced conjugate and linker technologies, more potent payloads, and new antigen targets. According to the FDA's data published in May 2021, 113 clinical trials were in studies for 77 novel antibody-drug conjugates that targeted over 40 different targets. As of January 2021, the US Food and Drug Administration (FDA) had approved Mylotarg, Lumoxiti, Adcetris, Kadcyla, Enhertu, Trodelvy, Besponsa, Polivy, Padcev, and Blenrep for several cancer indications. In September 2021, the FDA expedited the approval of Tivdak (tisotumab vedotin-tftv), developed by Seagen and Genmab. This treatment is a conjugate that combines a tissue factor-directed antibody with a microtubule inhibitor. It is administered as an intravenous infusion and is intended for women with recurrent or metastatic cervical cancer that has progressed during or after chemotherapy. Further, in 2023, AstraZeneca's Truqap (capivasertib) and Faslodex (fulvestrant) received regulatory approval in the US for the treatment of adult patients suffering from HR-positive and HER2-negative locally advanced or metastatic breast cancer with biomarker alterations (PIK3CA, AKT1, or PTEN). Growing business expansion activities by companies in the antibody-drug conjugate market in the US to strengthen their market positions in different regions further support the antibody-drug conjugate market growth.
North America Antibody Drug Conjugates Market Company ProfilesSome of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA.
These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
North America Antibody Drug Conjugates Market Research MethodologyThe following methodology has been followed for the collection and analysis of data presented in this report:
Secondary Research
The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Company websites,
annual reports, financial statements, broker analyses, and investor presentationsIndustry trade journals
and other relevant publicationsGovernment documents,
statistical databases, and market reportsNews articles,
press releases, and webcasts specific to companies operating in the market
Note:
All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.Primary Research
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
- Validate and refine findings from secondary research
- Enhance the expertise and market understanding of the analysis team
- Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
Industry stakeholders:
Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales ManagersExternal experts:
Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. Antibody Drug Conjugates Market Landscape
4.1 PEST Analysis
4.2 Ecosystem Analysis
4.2.1 Raw Materials and Sourcing
4.2.2 Manufacturing Processes
4.2.3 Regulatory Compliance
4.2.4 Distribution and Logistics
4.2.5 List of Vendors in the Value Chain
5. North America Antibody Drug Conjugates Market - Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. Antibody Drug Conjugates Market - North America Market Analysis
6.1 North America Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
6.2 North America Antibody Drug Conjugates Market Forecast and Analysis
7. North America Antibody Drug Conjugates Market Revenue Analysis - by Technology
7.1 Cleavable Linker
7.1.1 Overview
7.1.2 Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Non-cleavable Linker
7.2.1 Overview
7.2.2 Non-cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. North America Antibody Drug Conjugates Market Revenue Analysis - by Application
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Brain Cancer
8.2.1 Overview
8.2.2 Brain Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.4 Ovarian Cancer
8.4.1 Overview
8.4.2 Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.5 Lung Cancer
8.5.1 Overview
8.5.2 Lung Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. North America Antibody Drug Conjugates Market Revenue Analysis - by Target
9.1 HER2
9.1.1 Overview
9.1.2 HER2: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 CD22
9.2.1 Overview
9.2.2 CD22: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 CD30
9.3.1 Overview
9.3.2 CD30: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. North America Antibody Drug Conjugates Market Revenue Analysis - by Distribution Channel
10.1 Retail Pharmacies
10.1.1 Overview
10.1.2 Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Hospital Pharmacies
10.2.1 Overview
10.2.2 Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. North America Antibody Drug Conjugates Market - Country Analysis
11.1 North America
11.1.1 North America Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.1.1 North America Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.2.2 United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 United States: North America Antibody Drug Conjugates Market Share - by Technology
11.1.2.2.2 United States: North America Antibody Drug Conjugates Market Share - by Application
11.1.2.2.3 United States: North America Antibody Drug Conjugates Market Share - by Target
11.1.2.2.4 United States: North America Antibody Drug Conjugates Market Share - by Distribution Channel
11.2.3.3 Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Canada: North America Antibody Drug Conjugates Market Share - by Technology
11.2.3.3.2 Canada: North America Antibody Drug Conjugates Market Share - by Application
11.2.3.3.3 Canada: North America Antibody Drug Conjugates Market Share - by Target
11.2.3.3.4 Canada: North America Antibody Drug Conjugates Market Share - by Distribution Channel
11.3.4.4 Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 Mexico: North America Antibody Drug Conjugates Market Share - by Technology
11.3.4.4.2 Mexico: North America Antibody Drug Conjugates Market Share - by Application
11.3.4.4.3 Mexico: North America Antibody Drug Conjugates Market Share - by Target
11.3.4.4.4 Mexico: North America Antibody Drug Conjugates Market Share - by Distribution Channel
12 Competitive Landscape
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 Industry Landscape
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 GSK Plc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Pfizer Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bristol-Myers Squibb Co
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Johnson & Johnson
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Takeda Pharmaceutical Co Ltd
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 AstraZeneca Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Astellas Pharma Inc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AbbVie Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Merck KGaA
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
14.11 Gilead Sciences Inc
14.11.1 Key Facts
14.11.2 Business Description
14.11.3 Products and Services
14.11.4 Financial Overview
14.11.5 SWOT Analysis
14.11.6 Key Developments
14.12 BioNTech SE
14.12.1 Key Facts
14.12.2 Business Description
14.12.3 Products and Services
14.12.4 Financial Overview
14.12.5 SWOT Analysis
14.12.6 Key Developments
14.13 Daiichi Sankyo Co Ltd
14.13.1 Key Facts
14.13.2 Business Description
14.13.3 Products and Services
14.13.4 Financial Overview
14.13.5 SWOT Analysis
14.13.6 Key Developments
14.14 RemeGen Co Ltd
14.14.1 Key Facts
14.14.2 Business Description
14.14.3 Products and Services
14.14.4 Financial Overview
14.14.5 SWOT Analysis
14.14.6 Key Developments
14.15 ADC Therapeutics SA
14.15.1 Key Facts
14.15.2 Business Description
14.15.3 Products and Services
14.15.4 Financial Overview
14.15.5 SWOT Analysis
14.15.6 Key Developments
15. Appendix
15.1 About The Insight Partners
List of Tables
Table 1. North America Antibody Drug Conjugates Market Segmentation
Table 2. List of Vendors
Table 3. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 5. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 6. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 7. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 8. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 10. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 12. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 13. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 14. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 15. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 16. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 17. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 18. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 19. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 20. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 21. Heat Map Analysis by Key Players
List of Figures
Figure 1. North America Antibody Drug Conjugates Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Antibody Drug Conjugates Market
Figure 4. North America Antibody Drug Conjugates Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
Figure 7. North America Antibody Drug Conjugates Market Share (%) - by Technology, 2023 and 2031
Figure 8. Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Non-cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. North America Antibody Drug Conjugates Market Share (%) - by Application, 2023 and 2031
Figure 11. Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Brain Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Lung Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. North America Antibody Drug Conjugates Market Share (%) - by Target, 2023 and 2031
Figure 18. HER2: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. CD22: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. CD30: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. North America Antibody Drug Conjugates Market Share (%) - by Distribution Channel, 2023 and 2031
Figure 23. Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. North America Antibody Drug Conjugates Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 27. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Company Positioning & Concentration
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For